Owkin Spinoff Waiv Bags $33M to Sharpen Cancer Testing With AI
Paris-based Waiv raised $33M to build AI-powered cancer diagnostics after spinning out of biotech unicorn Owkin.
Waiv, a Paris-based healthtech startup, just pulled in $33 million in funding. Its mission: use AI to make cancer testing significantly more precise.
The company spun out of Owkin, the French biotech unicorn that built its name on AI-driven diagnostics and drug discovery. Now Waiv is striking out on its own with a dedicated focus on revolutionizing cancer screening.
The funding gives Waiv serious runway to develop and scale its AI-powered medical testing platform. Cancer diagnostics is a massive market, and the promise of catching disease earlier and more accurately is exactly the kind of pitch that opens investor wallets.
Owkin has been a prolific spawning ground for healthtech innovation, and Waiv represents its latest bet that spinning out focused teams can move faster than keeping everything under one roof.